Singapore markets open in 3 minutes
  • Straits Times Index

    +26.50 (+0.89%)
  • S&P 500

    -50.57 (-1.31%)
  • Dow

    -121.43 (-0.39%)
  • Nasdaq

    -361.04 (-2.70%)

    +2,624.37 (+5.43%)
  • CMC Crypto 200

    +31.84 (+3.22%)
  • FTSE 100

    +61.72 (+0.93%)
  • Gold

    -2.90 (-0.17%)
  • Crude Oil

    -0.03 (-0.05%)
  • 10-Yr Bond

    +0.0550 (+3.89%)
  • Nikkei

    -334.07 (-1.13%)
  • Hang Seng

    +784.56 (+2.70%)
  • FTSE Bursa Malaysia

    +18.58 (+1.18%)
  • Jakarta Composite Index

    +17.55 (+0.28%)
  • PSE Index

    +23.22 (+0.34%)

Advanced Antibodies, 2020 Report Profiles Key Companies Which are Highly Innovative and Primed for Growth in the Near Term -

·2-min read

The "Advanced Antibodies, 2020" report has been added to's offering.

This report profiles companies (excluding Tier 1 pharma/biopharma companies), which are highly innovative and primed for growth in the near term. It has excluded companies, which have candidates in pre-clinical/phase 1 development, and is focused on companies, which would have a near term commercial realization.

With advances in antibody-based therapies, bispecific antibodies (bsAbs) have gained momentum in the last few years after the regulatory approvals of Amgen's blinatumomab (Blincyto) and Chugai's Hemlibra for Hemophilia A. The key advantage of bsAbs lies in their ability to bind two different epitopes or antigens, thereby overcoming the limitations of monoclonal antibodies, which can only bind to a single epitope. Bispecific antibodies represent a highly promising class of therapeutics and were conceptualized more than 5 decades ago, but challenges associated with protein engineering, immunogenicity, stability, and manufacturing have dampened their commercialization.

Bispecific antibodies (bispecifics) are considered as the next gen antibody therapeutics, which could be used in cancer treatment for better cytotoxic effects, and also hold promise for certain therapeutic applications ,which are complex and refractory to other modalities, such as immune cell retargeting, site-specific targeting, and CNS targeting.

With several advanced antibody engineering technologies in place- bispecific antibodies are demonstrating a high potential to transform cancer immunotherapy landscape, and also bring about a significant change in the treatment of infectious diseases and autoimmune diseases.

Key Topics Covered:

1. Strategic Imperative and Growth Environment

  • Strategic Imperative

  • Growth Environment

2. The Advanced Antibodies

3. Companies to Action:

  • Affimed Therapeutics GmbH

  • AlphaMab Oncology

  • Chugai

  • EpimAb Biotherapeutics

  • Genmab

  • Macrogenics Inc.

  • Merus NV

  • Xencor

  • Zymeworks

4. Strategic Insights

5. Next Steps: Leveraging The Radar to Empower Key Stakeholders

  • Significance of Being on the The Radar

  • The Radar Empowers the CEO's Growth Team

  • The Radar Empowers Investors

  • The Radar Empowers Customers

  • The Radar Empowers the Board of Directors

  • The Radar Analytics

  • The Radar: Benchmarking Future Growth Potential

For more information about this report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900